Cinqaero 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification0F
Decision 
Information 
1 issued on 
Issued1F
2 / 
affected2F
3  
amended 
on 
IB/0048 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
26/05/2023 
SmPC 
Product information section 6.3 is updated to reflect the 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
shelf-life extension of the finished product CINQAERO 
10 mg/mL concentrate for solution for infusion as packaged 
for sale from 3 years to 4 years when stored at 2 – 8 °C. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IB/0047/G 
This was an application for a group of variations. 
03/05/2023 
n/a 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
IB/0046 
C.I.11.z - Introduction of, or change(s) to, the 
12/12/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0045/G 
This was an application for a group of variations. 
03/11/2022 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.2.d - Change in test procedure for the finished 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Other changes to a test procedure 
(including replacement or addition) 
IB/0044 
B.I.b.2.z - Change in test procedure for AS or 
13/09/2022 
n/a 
starting material/reagent/intermediate - Other 
variation 
IB/0043 
B.I.b.2.z - Change in test procedure for AS or 
05/04/2022 
n/a 
starting material/reagent/intermediate - Other 
variation 
IB/0042/G 
This was an application for a group of variations. 
06/01/2022 
n/a 
B.II.d.2.b - Change in test procedure for the finished 
product - Deletion of a test procedure if an 
alternative method is already authorised 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
IB/0041 
B.II.b.3.a - Change in the manufacturing process of 
07/12/2021 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
N/0040 
Minor change in labelling or package leaflet not 
08/10/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10523
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202102 
reslizumab 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R/0038 
Renewal of the marketing authorisation. 
25/03/2021 
01/06/2021 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Cinqaero in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
II/0037/G 
This was an application for a group of variations. 
19/11/2020 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
PSUSA/10523
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202002 
reslizumab 
IB/0036 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
17/09/2020 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0035 
B.I.a.2.a - Changes in the manufacturing process of 
01/09/2020 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0034 
B.III.2.a.2 - Change of specification(s) of a former 
21/07/2020 
n/a 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Member State - Excipient/AS starting material 
IB/0033 
B.I.a.2.a - Changes in the manufacturing process of 
13/07/2020 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IA/0032 
B.II.d.2.a - Change in test procedure for the finished 
25/05/2020 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0030/G 
This was an application for a group of variations. 
21/04/2020 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
IA/0029 
B.II.b.5.a - Change to in-process tests or limits 
26/03/2020 
n/a 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
IB/0028/G 
This was an application for a group of variations. 
11/03/2020 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
IA/0027 
A.5.a - Administrative change - Change in the name 
22/11/2019 
05/11/2020 
SmPC, Annex 
and/or address of a manufacturer/importer 
II and PL 
responsible for batch release 
PSUSA/10523
Periodic Safety Update EU Single assessment - 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
/201902 
reslizumab 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0025 
B.I.b.2.e - Change in test procedure for AS or 
16/04/2019 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IA/0024 
B.II.b.5.a - Change to in-process tests or limits 
29/03/2019 
n/a 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
PSUSA/10523
Periodic Safety Update EU Single assessment - 
14/03/2019 
n/a 
PRAC Recommendation - maintenance 
/201808 
reslizumab 
IAIN/0023 
B.II.b.2.c.1 - Change to importer, batch release 
10/01/2019 
10/12/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0022/G 
This was an application for a group of variations. 
09/01/2019 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
N/0021 
Minor change in labelling or package leaflet not 
15/11/2018 
10/12/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0019/G 
This was an application for a group of variations. 
19/10/2018 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0018 
Transfer of Marketing Authorisation 
30/08/2018 
20/09/2018 
SmPC, 
Labelling and 
PL 
IB/0017 
B.II.d.2.d - Change in test procedure for the finished 
20/09/2018 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
PSUSA/10523
Periodic Safety Update EU Single assessment - 
06/09/2018 
n/a 
PRAC Recommendation - maintenance 
/201802 
reslizumab 
PSUSA/10523
Periodic Safety Update EU Single assessment - 
08/03/2018 
n/a 
PRAC Recommendation - maintenance 
/201708 
reslizumab 
IB/0015/G 
This was an application for a group of variations. 
14/12/2017 
20/09/2018 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Labelling and 
PL 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IB/0014 
C.I.11.z - Introduction of, or change(s) to, the 
05/12/2017 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0012 
B.I.b.z - Change in control of the AS - Other 
04/10/2017 
n/a 
variation 
PSUSA/10523
Periodic Safety Update EU Single assessment - 
28/09/2017 
n/a 
PRAC Recommendation - maintenance 
/201702 
reslizumab 
II/0005/G 
This was an application for a group of variations. 
23/03/2017 
28/04/2017 
SmPC, Annex 
The Marketing Authorisation Holder has introduced a 25 mg 
Update of section 4.2 of the SmPC in order to include 
and PL 
reslizumab supports a vial based dosing regimen. 
II, Labelling 
presentation (2.5 ml fill/10 mg/mL). This presentation of 
a revised dosing regimen as a result of the new 
25mg vial presentation in section 2. Consequential 
B.II.e.5c variation to change the pack size of the 
finished product and update sections 6.5 and 6.6 of 
the SmPC. 
The Annex II, Package Leaflet, Labelling and Risk 
Management Plan v. 2.3 are updated accordingly. 
B.II.e.5.c - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
CINQAERO is given as intravenous infusion once every four 
weeks. The recommended dose is based on patient body 
weight and should only be adjusted for significant changes 
in body weight.For patients below 35 kg or above 199 kg: 
the recommended dose is 3 mg/kg body weight. The 
volume (in mL) required from the vial(s) should be 
calculated as follows: 0.3 x patient body weight (in kg). For 
patients between 35 kg and 199 kg: the recommended 
dose is achieved using the vial based dosing scheme 
(please refer to Table 1 in section 4.2 of the SmPC. 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0009/G 
This was an application for a group of variations. 
11/04/2017 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
IAIN/0010 
B.II.b.1.a - Replacement or addition of a 
07/04/2017 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0008 
B.II.b.3.a - Change in the manufacturing process of 
07/03/2017 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0007 
B.II.b.4.z - Change in the batch size (including batch 
01/02/2017 
n/a 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
size ranges) of the finished product - Other variation 
IB/0004 
B.II.d.2.d - Change in test procedure for the finished 
05/12/2016 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IB/0006/G 
This was an application for a group of variations. 
30/11/2016 
n/a 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
IA/0003 
A.7 - Administrative change - Deletion of 
27/10/2016 
n/a 
manufacturing sites 
IAIN/0001/G 
This was an application for a group of variations. 
20/09/2016 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 12/12 
 
 
 
 
 
 
